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Abstract 
Introduction: Multifactorial pathogenesis of diabetic kidney disease (DKD) consists of a combination of metabolic, environmental, and 
genetic factors. A genome-wide association study has shown that ELMO1 is a candidate gene for DKD occurrence and progression. The 
aim of this study was to assess the association of a single nucleotide polymorphism (rs741301) of the ELMO1 gene with DKD in Polish 
patients with type 2 diabetes (T2DM).
Material and methods: This was a case/control study of 272 T2DM patients with or without DKD. Patients were divided into groups 
depending on DKD definition according to the American Diabetes Association (ADA) and the National Kidney Foundation (NKF). 
The association of the rs741301 polymorphism with DKD was assessed in the whole study group as well as in the subgroups stratified 
according to the presence of DKD.
Results: There was no association between rs741301 polymorphisms and the presence of DKD in relation to the ADA definition 
(p = 0.6) or the NKF definition (p = 0.5) of DKD and with estimated glomelural filtration rate (eGFR) value reflecting the stage of the 
chronic kidney disease (p = 0.8).
Conclusions: Even though the results of this study are negative, there is still a great need for larger studies assessing the genetic suscep-
tibility to DKD to identify patients who are particularly prone to this complication. (Endokrynol Pol 2020; 71 (1): 66–72)
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Introduction
Diabetes mellitus is an enormous health problem. Its 
prevalence is estimated to rise from 425 million people 
in 2017 to 629 million by 2045 [1]; it has been described as 
a silent pandemic of the 21st century [2]. Approximately 
40% of those with type 2 diabetes (T2DM) develop dia-
betic kidney disease (DKD), which is a leading cause 
of end-stage renal disease (ESRD) globally [3]. Most of 
these patients actually die from cardiovascular diseases 
before they reach this final stage of chronic kidney 
disease (CKD) [4]. In Poland, there are almost 3 million 
people living with diabetes, and the precise occurrence 
of DKD is difficult to estimate because of a lack of spe-
cific registries; however, it is known that almost 44% of 
all ESRD is due to diabetes [5].
Diabetic kidney disease is recognised based on the 
existence of persistent increased urine albumin excre-
tion and/or decreased estimated glomerular filtration 
rate (eGFR) when other causes of CKD are excluded [3]. 
Diabetic kidney disease is often diagnosed at advanced 
stages [6] because it may have no clinical manifestation 
until ESRD occurs; thus, there is an unmet need to iden-
tify biomarkers that identify patients at early stages, to 
implement proper treatment. The multifactorial patho-
genesis of DKD consists of a combination of metabolic, 
environmental, and genetic factors [2]. There are no 
universal methods to identify patients who are prone to 
this complication; however, in view of the indisputable 
role of genetic factors, searching for candidate genes 
seems to be critical for scientific research.
A prior genome-wide association study (GWAS) 
identified genes with polymorphisms associated with 
increased incidence of DKD [7]. However, further 
studies to prove the role of these polymorphisms in 
DKD occurrence and progression in different diabetic 
populations are needed, in order to guide strategies 
that prevent and treat DKD. There are relatively few 
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sequence NC_000007.14:g.36878390C>T) with DKD in 
a group of Polish T2DM patients (the industrial region 
of Silesia, Poland).
Material and methods
Patients
This was a case/control study. We invited to participate in the 
study 329 consecutive, patients suffering from T2DM for at least 
10 years, treated in the Diabetology Outpatient Clinic in Zabrze, 
Poland. First of all, patients were divided into two study groups 
depending on the presence (the study group) or the absence of 
DKD (the control group). We initially used DKD diagnosis criteria 
proposed by ADA (UACR ≥ 30 mg/g present in two out of three 
urine samples). Furthermore, we chose to use DKD diagnosis 
criteria proposed by NKF, which were more restricted than those 
proposed by ADA, and we further divided the study group into 
a study subgroup of patients (UACR ≥ 30 mg/g in two out of three 
specimens when coexisting diabetic retinopathy was present or 
UACR > 300 mg/g in patients regardless of diabetic retinopathy) 
and a control subgroup of patients (without retinopathy and with 
UACR < 30 mg/g). The exclusion criteria for both study groups 
were as follows: type 1 diabetes mellitus, chronic interstitial ne-
phritis, chronic glomerulonephritis, cancer, or lack of informed 
consent. The study was approved by the Ethical Committee of 
the Medical University of Silesia and performed in accordance 
with ethical standards and with the 1964 Helsinki declaration 
as well as its later amendments. All participants gave written, 
informed consent.
Methods
Eligible patients were invited to participate in the study. During 
the first study visit, medical history collection based on medical 
documentation from the Diabetology Outpatient Clinic and a rou-
tine physical examination were performed the anthropometric 
parameters such as height (m) and weight (kg) being measured 
by standard methods, and the body mass index (BMI) was calcu-
lated (kg/m2). Blood pressure was measured (after five minutes 
of rest) three times, each five minutes apart in a sitting position 
by Microlife BP AG1-20 sphygmomanometer. Blood samples were 
collected from the subjects for biochemical analysis and DNA ex-
traction. Haemoglobin A1c was measured using high-performance 
liquid chromatography (HPLC), and the outcome was expressed 
in National Glycohemoglobin Standardisation Program/Diabetes 
Control and Complication Trial units [32]. Serum creatinine was 
determined with Jaffe’s method and estimated glomelural filtra-
tion rate (eGFR) per 1.73 m2 and was calculated according to the 
CKD-EPI formula [33]; these results were classified into five stages 
of the disease (G1–G5) [34]. The UACR was estimated using im-
munoturbidimetric methods and was drawn from the patients’ 
medical history (we analysed three morning urine samples col-
lected over six months). Diabetic kidney disease was recognised 
based on elevated UACR after excluding other possible causes of 
elevated albuminuria (on the basis of physical examination and 
present and past medical history). Patients were examined by the 
same ophthalmologist to determine the presence and severity of 
diabetic retinopathy.
SNP genotyping
Genomic DNA was extracted from patients’ peripheral blood 
lymphocytes as follows: 4 mL of venous blood was collected into 
S-Monovette tubes (Sarstedt, 6.4 mg of potassium EDTA) and 
centrifuged for 10 minutes (1000 rpm, Sigma 3K15); the buffy coat 
was aspirated into 2 ml cryovials and stored at –20°C until DNA 
isolation. After defrosting, the material was transferred to 50 ml 
Falcon tubes (Sarstedt) and erythrocyte lysis buffer was added 
(0.32 mol/L sucrose, 0.01 mmol/L TrisHCL, 5 mmol/L magnesium 
Polish studies which emphaze gene polymorphisms 
and DKD; some proved an association [8,9], but others 
did not [10,11].
A genome-wide association study has shown the 
engulfment and cell motility 1 (ELMO1) gene to be 
a potential candidate gene for the development of DKD 
in various populations of patients, but it has not yet 
been studied in a Polish population. ELMO1 is located 
in humans on chromosome 7, and the most significant 
single nucleotide polymorphism (SNP) is rs741301 
[12–15]. Engulfment and Cell Motility (ELMO) is 
a soluble cytoplasmic multifunctional signalling protein 
consisting of 720 amino acids. It promotes cytoskeleton 
reorganisation [16], cell migration [17], and phagocyto-
sis of apoptotic cells [18].
Sharma et al. recently published an elegant study us-
ing animal models to identify the role of ELMO1 in the 
renal development of zebrafish under hyperglycaemia. 
They confirmed the animal data with immunohisto-
chemical analysis of human kidneys from patients with 
DKD. Those authors concluded that the overexpression 
of the ELMO1 gene occurs due to the glomerular protec-
tion and survival of renal cells by decreasing apoptosis 
under hyperglycaemic conditions [19].
Subsequent studies confirmed the association of dif-
ferent SNP variants in the ELMO1 gene with susceptibil-
ity to DKD in patients from various populations: African 
Americans [20], European Americans [21], American 
Indians [22], Mexican Americans [23], Tunisian Arabs 
[24], as well as citizens of China [25], India [26–27], Iran 
[28], and Malaysia [29]. Unfortunately, it is impossible to 
draw a unified conclusion from the outcomes because 
these studies were different in terms of methodology 
and definition of DKD. Some of these patients pre-
sented with T2DM [20, 22–29], but others with type 1 
diabetes mellitus [21]. Some of the authors used the 
DKD definition according to ADA [3,28] whereas others 
according to NKF [12, 21, 25, 26, 30]. This discrepancy 
may be caused by a lack of coherence between DKD 
definitions across leading international diabetology and 
nephrology associations [3, 30]. The American Diabetes 
Association (ADA) suggests the diagnosis of DKD if the 
urine albumin-to-creatinine ratio (UACR) is ≥ 30 mg/g 
[3], and the National Kidney Foundation (NKF) diag-
nosis DKD if UACR is ≥ 30 mg/g only in patients with 
retinopathy; UACR > 300 mg/g in regardless of this 
complication [30]. Polish guidelines for the management 
of diabetes emphasise that screening for increased uri-
nary albumin excretion should be performed annually 
[31]. In light of the positive GWAS outcomes in relation 
to the ELMO1 gene and the contradictory outcomes of 
follow-up studies — as well as the lack of studies per-
formed in a Polish population — this study assessed the 
association of rs741301 ELMO1 gene variants (reference 
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chloride, and 1% Triton X-100). After 30 minutes of incubation at 
4°C, the material was centrifuged (10 minutes, 3000 rpm, 4°C, Sigma 
3K15). The supernatant was removed, and the leucocyte sediment 
was purified with lysis buffer again as before. DNA was extracted 
from the leucocyte sediment via a DNAzol Reagent (Life Technolo-
gies, USA) in accordance with the manufacturer’s instructions. The 
quality and quantity of DNA was examined with Gen Quant II 
(Pharmacia Biotech, Sweden).
The polymerase chain reaction (PCR) identified 188 base pairs (bp) 
with an rs741301 polymorphism. The reaction substrates were as 
follows: 2 µg DNA, 1.55 mmol/L magnesium chloride, 2 µg deoxy-
nucleoside triphosphates, 2 µg primer ELMO F 5’ – CAC AAC TGT 
CTC AAC AGT CTG – 3’, and 2 µg primer ELMO R 5’ – GCA ATA 
GAT TTT ATG AGG TGG TAG – 3’, and 0.5 units of DNA polymerase 
DyNAzyme TMII (Finnzymes). To create a cutting spot for the Alu 
I restriction enzyme, C was substituted with T in the primer. PCR 
thermal cycles were as follows: denaturation at 94°C for 5 minutes 
and then 35 cycles: 1 minute at 94°C, 1 minute at 55°C, and 1.5 min-
utes at 72°C; the end was 10 minutes at 72°C. Digestion with Alu 
I restriction enzyme lasted 2 hours at 37°C. The PCR product was 
dispersed via electrophoresis on agarose gel with 3% ethidium 
bromide enabling DNA visualisation in UV. Allele G created a cut-
ting spot for Alu I, resulting in two DNA bands (164 and 24 bp). 
Allele A had no cutting spot for the enzyme, and the DNA band was 
188 bp long. The method was validated within the laboratory. The 
length of the fragments was estimated in comparison with a 50 bp 
long DNA Ladder (Fermentas). The results were documented via 
a ViberLourmet with a UV transilluminator. Figure 1 presents the 
distribution of allele G and A as well as the homozygous AA and 
GG genotypes and the heterozygous genotype AG.
Statistical analysis
All statistical calculations were performed using Microsoft Of-
fice Excel and Statistica 12.0 (StatSoft Inc., USA) software. The 
Shapiro-Wilk normality test was used to establish the distribution 
of quantitative variables. Descriptive statistics for continuous 
parameters of normal distribution are presented as the arithmetic 
means (standard deviation (SD). Median values with interquartile 
range are presented for continuous data that did not have normal 
distribution. Absolute values and percentages are given for categori-
cal and qualitative variables.
Comparative analyses were performed with the t-test or Mann-
-Whitney U-test for variables with normal distribution and other 
types of distribution, respectively. Accordance with Hardy-Wein-
berg equilibrium was tested with Pearson’s c2 test with Yates correc-
tion. A p value of < 0.05 was considered to be statistically significant.
Results
From the total of 329 eligible patients enrolled into the 
study, 57 were not included for further analysis for vari-
ous reasons listed in Figure 2. There were 272 patients 
enrolled into the final analysis [170 women (62.5%)] in 
a mean (SD) age of 63.7 (8) years and with mean (SD) 
duration of T2DM of 14.1 (6.3) years. Our first intention 
was to divide the whole study group into two groups; 
namely, the study group (n = 117) consisting of patients 
with T2DM and DKD defined according to ADA DKD 
criteria (which are less restricted than DKD diagnosis 
criteria proposed by NKF, which require retinopathy 
coexistence or higher UACR value for diagnosis) and 
the control group (n = 155) of patients with T2DM 
but without DKD. Because there was no association of 
studied polymorphism found when these groups were 
analysed, we decided to check whether there could 
be an association found when the diagnosis criteria 
for DKD were exacerbated, as in the case of criteria 
proposed by NKF, in which the UACR has to be higher 
or coexisting retinopathy is required. Hence, we took 
a closer look into the study group of 117 patients with 
DKD according to ADA criteria, and the subgroup of 
patients with DKD according to NKF criteria emerged 
(n = 79). From the control group of patients without 
DKD we distinguished a control subgroup (n = 72) of 
patients without retinopathy.
The basic demographic and clinical characteristics of 
the study and control groups are shown in Table 1 and 
Table 2. There were 55 patients with UACR 30–300 mg/g 
and 62 with UACR > 300 mg/g in the study group 
(Tab.  1). There were no patients who fulfilled the 
ADA criteria of DKD related solely to lower eGFR, i.e. 
there were 27 patients with decreased eGFR below 
60 mL/min/1.73 m2 who did not have elevated UACR 
but had other causes of CKD (such as recurrent infec-
tions and chronic interstitial nephritis) and therefore 
were enrolled into the control group. The genotype 
frequency distribution among the study and control 
groups and subgroups were in agreement with the 
Hardy-Weinberg equilibrium (Tab. S1 and S2 in supple-
mentary materials, respectively). There was no asso-
ciation between the rs741301 polymorphism and the 
presence of DKD in the control group (Tab. 3, p = 0.6) 
nor with eGFR reflecting the CKD stage (Tab. 4, p = 0.8). 
There was also no association between the examined 
SNP and DKD in the study subgroup (DKD defined 
according to NKF criteria) (Tab. 5, p = 0.5). Additionally, 
there were no significant differences between studied 
groups according to gender (p = 0.6) or smoking status 
(p = 0.09). Moreover, the studied groups did not differ 
significantly in terms of hypertension (p = 0.2, Tab. 1) 
and ACEI use (p = 0.09, Tab. 1).
Discussion
Diabetic kidney disease is the leading cause of ESRD 
and is often diagnosed at its late stages moreover 
genetic factors have a clear role in its development. 
Therefore, genetic markers can potentially be used for 
early diagnosis of DKD. The GWAS study has shown 
Figure 1. Distribution of allele A ang G of the ELMO1 gene 
documented via ViberLourmet with a UV transilluminator
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Table 1. Demographic and clinical characteristics of study and control group 
Parameters Studya (n = 117) Controlb (n = 155) p
Age (years) 63.1 (8.4) 64.1 (7.7) 0.35
Diabetes duration (years) 12.3 (6.7) 15.5 (5.7) 0.05
BMI [kg/m2] 28.82 (4.5) 29.33 (4.3) 0.38
SBP [mm Hg] 151 (22.3) 145.3 (19.9) 0.03
DBP [mm Hg] 82.5 (12.4) 85.3 (11.9) 0.07
HbA1c (%) [mmol/mol]
8.98 (1.9) 
(75 [15.9])
8.81 (1.6)
(73 [13.3])
0.03
Creatinine [mmol/L] 115.93 (114.8) 71.92 (31.8) 0.0013
eGFR [mL/min/1.73 m2] 73.48 (29.8) 81.52 (22.0) 0.0004
UACR [mg/g] 770.3 (835.7) 11.75 (9.5) 0.0000
Number of patients with UACR in range of 30–300 mg/g (n) 55 0 0.0000
Number of patients with UACR > 300 mg/g (n) 62 0 0.0000
Hypertension [n (%)] 110 (94) 139 (90) 0.2
ACEI [n (%)] 49 (42) 50 (32) 0.09
ACEI — angiotensin-converting-enzyme inhibitors; BMI — body mass index; DBP — diastolic blood pressure; eGFR — estimated glomerular filtration rate;  
HbA1c — haemoglobin A1c; n — number of patients; p — statistical significance; SBP — systolic blood pressure; UACR — urinary albumin/creatinine ratio; 
aDKD (+) according to the ADA 2018 definition; bDKD (–) according to the ADA 2018 definition
Data are presented as mean (SD)
Figure 2. Patient’s assignment to groups. T2DM — type 2 diabetes mellitus; UACR — urine albumin/creatinine ratio; 
ADA — American Diabetes Association; NKF — National Kidney Foundation
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that the rs741301 polymorphism of the ELMO1 gene is 
a candidate diagnostic gene for DKD. We chose rs741301 
polymorphism of ELMO1 gene as a candidate gene for 
DKD based upon findings from previous studies, but 
these prior studies are contradictory [12, 20–29]. To the 
best of our knowledge, none of the prior studies as-
sessed the role of the ELMO1 gene with DKD among 
Polish patients. Moreover, none of these studies ap-
plied the two available (ADA and NKF) definitions of 
DKD in one study. This makes it impossible to perform 
a direct comparison of the studies performed to date. 
Our study comprised 272 Polish T2DM patients from 
Silesia region. No association was seen between the 
rs741301 polymorphism of the ELMO1 gene and DKD 
regardless of the criteria used to diagnose DKD. The 
allelic frequency observed in the European population 
is G: 0.322 and A: 0.678 [35] and is comparable to the 
frequency seen in the presented study.
Even though this study obtained a negative re-
sult, our findings are consistent with some studies 
exploring the association of ELMO1 gene with DKD 
performed in other ethnic groups. Kim et al. examined 
almost 900 people of Mexican-American descent. Most 
suffered from T2DM, but the authors did not prove 
the association between ELMO1 and DKD. In that 
study, most of the patients had ESRD and diabetes as 
Table 2. Demographic and clinical characteristics of study and control subgroup
Parameters Study subgroupa (n = 79) Control subgroupb (n = 72) p
Age (years) 62.84 (7.94) 65.75 (7.06) 0.41
Diabetes duration (years) 14.9 (6.7) 16.75 (5.1) 0.11
BMI [kg/m2] 28.97 (4.8) 28.86 (4.3) 0.56
SBP [mm Hg] 153.8 (25.7) 144.1 (19.9) 0.05
DBP [mm Hg] 83.5 (14.2) 84.6 (11.9) 0.71
HbA1c (%) [mmol/mol]
9.25 (1.8) 
[78 (15.2)]
9.11 (1.5) 
[76 (12.2)] 0.65
Creatinine [mmol/L] 103.4 (55.4) 79.4 (67.5) 0.006
eGFR [mL/min/1.73 m2] 71.2 (30.0) 79.4 (19.1) 0.008
UACR [mg/g]  926.9 (1214.3) 12.39 (12.1) 0.0000
BMI — body mass index; DBP — diastolic blood pressure; eGFR — estimated glomerular filtration rate; HbA1c — haemoglobin A1c; n — number of patients; 
p — statistical significance; SBP — systolic blood pressure; UACR — urinary albumin/creatinine ratio; aDKD (+) according to the NKF definition; bDKD (–) according to 
the NKF definition
Data are presented as mean (SD)
Table 4. Distribution of the genotype frequencies of rs741301 ELMO1 gene in relation to chronic kidney disease (CKD) stage 
(p = 0.8; based on c2 Pearson test)
CKD stage G1 (n = 83)
G2 
(n = 128)
G3
G4 
(n = 8)
G5 
(n = 4)G3a 
(n = 33) 
G3b 
(n = 16)
Genotype AA [n (%)] 39 (30) 63 (48) 15 (11) 11 (8) 2 (2) 1 (1)
Genotype AG [n (%)] 36 (33) 49 (45) 13 (11) 4 (4) 4 (4) 3 (3)
Genotype GG [n (%)] 8 (25) 16 (50) 5 (16) 1 (3) 2 (6) 0 (0)
Data are presented as absolute values (percentages)
Table 3. Distribution of the genotype frequencies of rs741301 
ELMO1 gene in the study and control group (p = 0.6; based 
on c2 Pearson test)
Genotype A/A A/G G/G
Study 53 (45) 48 (41) 16 (14)
Control 78 (50) 61 (40) 16 (10)
Data are presented as absolute values (percentages)
Table 5. Distribution of the genotype frequencies of rs741301 
ELMO1 gene in the study and control subgroup (p = 0.5; 
based on c2 Pearson test)
Genotype A/A A/G G/G
Study subgroup [n (%)] 36 (46) 35 (44) 8 (10)
Control subgroup [n (%)] 37 (51) 25 (35) 10 (14)
Data are presented as numbers (percentages)
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a cause of DKD diagnosed based on various criteria 
[23]. Similarly, Hanson et al. showed no association of 
the ELMO1 gene with DKD in Pima Indians of Arizona, 
who have a high rate of DKD. Thus, the association 
may be strongly dependent on genetic background. 
These authors studied 12 SNPs of the ELMO1 gene 
including rs741301 among 141 patients with DKD 
based on protein-to-creatinine ratio and 416 T2DM 
patients without DKD. The authors suggest that the 
relationship between ELMO1 gene variations and 
DKD may have some functional variants or complex 
and undiscovered interactions with other biological 
factors [22]. This study stays in line with Yadav et al. 
in northern India, who examined 417 T2DM patients 
of whom 202 presented DKD based on reduced eGFR 
and proteinuria exceeding 500 mg/day along with reti-
nopathy. They noticed a higher incidence of rs741301 
in patients with diabetes compared to healthy controls, 
but there was no association of this variant with DKD 
[27]. Similarly, Yahya et al. examined 820 patients from 
Malaysia and concluded that SNP rs741301 does not 
contribute to DKD [29].
Other studies proved an association of rs741301 
with DKD. Shimazaki et al. examined 94 patients 
with DKD (defined as an overt nephropathy — uri-
nary albumin excretion rates ≥ 200 µg/min or UACR 
ratio ≥ 300 mg/g or chronic renal-replacement thera-
py) with coexisting diabetic retinopathy and 96 con-
trols without renal dysfunction. They proved that the 
G allele and the GG genotype of the rs741301 variant 
of ELMO1 gene increases susceptibility to DKD and 
plays an important role both in the development and 
progression of this complication [12]. Mehrabzadeh 
et al. studied 300 Iranians (100 healthy volunteers, 
100 with DKD defined as UACR ≥ 30 mg/g or protein 
excretion history due to diabetes, and 100 patients 
with T2DM without DKD, i.e. UACR < 30 mg/g) [28]. 
They also found a key role of the G allele and the GG 
genotype of the rs741301 variant of the ELMO1 gene 
as a candidate marker for DKD susceptibility. Inter-
estingly, contradictory conclusions were drawn by 
Wu et al. conducting a case-control study on a group 
of 200 unrelated T2DM Chinese patients (123 with 
DKD diagnosed as UACR ≥ 300 mg/g or renal replace-
ment therapy; 77 patients with UACR < 30 mg/g as 
controls). Their results suggested that the risk allele 
of DKD is allele A and not allele G as in the other 
studies [25].
Our study has some limitations. Only one SNP was 
examined, and the sample size was relatively small; 
however, this is only a preliminary report, and larger 
studies may give more information, especially since 
there has been no such study performed among Polish 
patients with diabetes.
Conclusion
In conclusion, our study did not prove an association 
between DKD and the ELMO1 gene in Polish popula-
tion of patients. There is still a great need for larger 
studies to identify patients who are particularly prone 
to this diabetic complication. We emphasise that nega-
tive studies are of great value in medicine; and such 
should not be underestimated because they can guide 
the direction of future studies [36].
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